Literature DB >> 21686950

Lymphoproliferative disorder due to sulphasalazine.

Shirish Dubey1, A O Adebajo.   

Abstract

We present the case of a 57-year-old man who had been on sulphasalazine for 20 years for seropositive non-erosive rheumatoid arthritis and developed a lymphoproliferative disorder, which resolved completely on cessation of sulphasalazine. This is the first report of lymphoproliferative disorder secondary to sulphasalazine. Lymphoproliferative disorders are well recognised with methotrexate and cyclosporine, and recognition of this disorder is critical due to the fact that a number of patients' symptoms will resolve completely with discontinuation of the drug and will not need further treatment. This case report discusses the literature on lymphoproliferative disorders as well as differential diagnoses like drug rash with eosinophilia and systemic symptoms (DRESS) syndrome.

Entities:  

Year:  2009        PMID: 21686950      PMCID: PMC3027684          DOI: 10.1136/bcr.06.2008.0038

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.

Authors:  Yoshihiko Hoshida; Jing-Xian Xu; Shigeki Fujita; Itsuko Nakamichi; Jun-Ichiro Ikeda; Yasuhiko Tomita; Shin-Ichi Nakatsuka; Jun-Ichi Tamaru; Atsushi Iizuka; Tsutomu Takeuchi; Katsuyuki Aozasa
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

2.  DRESS syndrome induced by sulphasalazine in rheumatoid arthritis.

Authors:  Ismail Bejia; Sameh Ben Hammouda; Kaouther Riahi; Farah Zinelabidine; Bahia Mediouni; Mongi Touzi; Naceur Bergaoui
Journal:  Joint Bone Spine       Date:  2006-03-20       Impact factor: 4.929

Review 3.  Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.

Authors:  E Salloum; D L Cooper; G Howe; J Lacy; G Tallini; J Crouch; M Schultz; J Murren
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

4.  Salazopyrin in the Treatment of Rheumatoid Arthritis.

Authors:  R J Sinclair; J J Duthie
Journal:  Ann Rheum Dis       Date:  1949-09       Impact factor: 19.103

5.  Reversible Hodgkin's lymphoma associated with Epstein-Barr virus occurring during azathioprine therapy for SLE.

Authors:  S J Evans; D K Watson; M O'Sullivan
Journal:  Rheumatology (Oxford)       Date:  2008-05-09       Impact factor: 7.580

6.  Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period.

Authors:  C Hiesse; P Rieu; F Kriaa; J R Larue; C Goupy; N Neyrat; B Charpentier
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

7.  Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis.

Authors:  O W Kamel; M van de Rijn; L M Weiss; G J Del Zoppo; P K Hench; B A Robbins; P G Montgomery; R A Warnke; R F Dorfman
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

8.  Involvement of nuclear factor-kappa B (NF-kappaB) activation in mitogen-induced lymphocyte proliferation: inhibitory effects of lymphoproliferation by salicylates acting as NF-kappaB inhibitors.

Authors:  L Cavallini; M A Francesconi; F Zoccarato; A Alexandre
Journal:  Biochem Pharmacol       Date:  2001-07-01       Impact factor: 5.858

9.  Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization.

Authors:  Luca Quartuccio; Valli De Re; Martina Fabris; Alessandra Marzotto; Nicoletta Franzolini; Daniela Gasparotto; Laura Caggiari; Gianfranco Ferraccioli; Cathryn Anne Scott; Salvatore De Vita
Journal:  Haematologica       Date:  2006-05       Impact factor: 9.941

10.  Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis.

Authors:  Annabel Maruani; Ewa Wierzbicka; Marie-Christine Machet; Myriam Abdallah-Lotf; Anne de Muret; Laurent Machet
Journal:  J Am Acad Dermatol       Date:  2007-11       Impact factor: 11.527

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.